CD133+CD44+ population efficiently enriches colon cancer initiating cells - PubMed (original) (raw)
. 2008 Oct;15(10):2927-33.
doi: 10.1245/s10434-008-0074-0. Epub 2008 Jul 29.
Affiliations
- PMID: 18663533
- DOI: 10.1245/s10434-008-0074-0
CD133+CD44+ population efficiently enriches colon cancer initiating cells
Naotsugu Haraguchi et al. Ann Surg Oncol. 2008 Oct.
Abstract
Background: Previous reports have demonstrated that CD133(+) cells or CD44(+) cells might be cancer initiating cells (CIC) of colon cancer. However, the association between the two cell types is unclear. In this study, we evaluated the tumorigenicity of each population of human colon cancer divided by CD133 and CD44 using non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice.
Methods: Using the colon cancer cell lines HT29 and Caco2 we evaluated the change of expression status of CD133 or CD44 by a treatment with sodium butyrate (NaBT) that can induce cellular differentiation. Next, we prepared ten clinical samples of colon cancer and analyzed the expression and tumorigenicity of CD133 and CD44.
Results: With NaBT treatment, CD44 expression was greatly downregulated in both HT29 and Caco2 (HT29: nontreatment versus treatment; 77.8% versus 0.6%, Caco2: 14.0% versus 0.4%, respectively), more than CD133 expression (HT29: nontreatment versus treatment; 90.1% versus 67.7%, Caco2: 98.9% versus 76.3%, respectively). In clinical samples, the percentages of CD133(+) cells and CD44(+) cells varied from 0.3% to 82.0% (mean 35.5%), and from 11.5% to 58.4% (mean 30.0%), respectively. Subcutaneous injection of CD133(+) or CD44(+) cells made a tumor in all mice (3/3 and 4/4, respectively). The combined analysis of CD133 and CD44 revealed that only the CD133(+)CD44(+) population had the ability to produce a tumor (3/3).
Conclusion: The findings demonstrate that, at present, the CD133(+)CD44(+ ) population may be the best to identify tumor initiating cells of human colon cancer.
Similar articles
- CD49f-positive cell population efficiently enriches colon cancer-initiating cells.
Haraguchi N, Ishii H, Mimori K, Ohta K, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M. Haraguchi N, et al. Int J Oncol. 2013 Aug;43(2):425-30. doi: 10.3892/ijo.2013.1955. Epub 2013 May 24. Int J Oncol. 2013. PMID: 23708747 - CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
Rocco A, Liguori E, Pirozzi G, Tirino V, Compare D, Franco R, Tatangelo F, Palaia R, D'Armiento FP, Pollastrone G, Affuso A, Bottazzi EC, Masone S, Persico G, Nardone G. Rocco A, et al. J Cell Physiol. 2012 Jun;227(6):2686-93. doi: 10.1002/jcp.23013. J Cell Physiol. 2012. PMID: 21898409 - Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells.
Chen KL, Pan F, Jiang H, Chen JF, Pei L, Xie FW, Liang HJ. Chen KL, et al. Clin Exp Metastasis. 2011 Dec;28(8):751-63. doi: 10.1007/s10585-011-9407-7. Epub 2011 Jul 13. Clin Exp Metastasis. 2011. PMID: 21750907 - Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver.
Zou GM. Zou GM. J Cell Physiol. 2008 Dec;217(3):598-604. doi: 10.1002/jcp.21541. J Cell Physiol. 2008. PMID: 18651561 Review. - Colon cancer stem cells: implications in carcinogenesis.
Sanders MA, Majumdar AP. Sanders MA, et al. Front Biosci (Landmark Ed). 2011 Jan 1;16(5):1651-62. doi: 10.2741/3811. Front Biosci (Landmark Ed). 2011. PMID: 21196254 Free PMC article. Review.
Cited by
- Enhanced autophagy in colorectal cancer stem cells does not contribute to radio-resistance.
Yan C, Luo L, Goto S, Urata Y, Guo CY, Doi H, Kitazato K, Li TS. Yan C, et al. Oncotarget. 2016 Jul 19;7(29):45112-45121. doi: 10.18632/oncotarget.8972. Oncotarget. 2016. PMID: 27129175 Free PMC article. - Identification of thiostrepton as a novel therapeutic agent that targets human colon cancer stem cells.
Ju SY, Huang CY, Huang WC, Su Y. Ju SY, et al. Cell Death Dis. 2015 Jul 2;6(7):e1801. doi: 10.1038/cddis.2015.155. Cell Death Dis. 2015. PMID: 26136074 Free PMC article. - Wnt/β-catenin Signaling Inhibitors suppress the Tumor-initiating properties of a CD44+CD133+ subpopulation of Caco-2 cells.
Kim J, Choi KW, Lee J, Lee J, Lee S, Sun R, Kim J. Kim J, et al. Int J Biol Sci. 2021 Apr 12;17(7):1644-1659. doi: 10.7150/ijbs.58612. eCollection 2021. Int J Biol Sci. 2021. PMID: 33994850 Free PMC article. - Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.
Grunt TW, Hebar A, Laffer S, Wagner R, Peter B, Herrmann H, Graf A, Bilban M, Posch M, Hoermann G, Mayerhofer M, Eisenwort G, Zielinski CC, Selzer E, Valent P. Grunt TW, et al. Am J Cancer Res. 2015 Jan 15;5(2):560-74. eCollection 2015. Am J Cancer Res. 2015. PMID: 25973297 Free PMC article. - Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer.
Khelwatty SA, Essapen S, Bagwan I, Green M, Seddon AM, Modjtahedi H. Khelwatty SA, et al. Oncotarget. 2019 Mar 1;10(18):1704-1715. doi: 10.18632/oncotarget.26722. eCollection 2019 Mar 1. Oncotarget. 2019. PMID: 30899442 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous